Marshall Wace LLP Buys 825,143 Shares of OPKO Health, Inc. (NASDAQ:OPK)

Marshall Wace LLP raised its stake in OPKO Health, Inc. (NASDAQ:OPK - Free Report) by 856.5% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 921,487 shares of the biotechnology company's stock after purchasing an additional 825,143 shares during the quarter. Marshall Wace LLP owned 0.14% of OPKO Health worth $1,355,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Wells Fargo & Company MN lifted its position in OPKO Health by 14.9% in the fourth quarter. Wells Fargo & Company MN now owns 229,262 shares of the biotechnology company's stock valued at $337,000 after purchasing an additional 29,738 shares during the last quarter. Cibc World Markets Corp bought a new position in shares of OPKO Health during the fourth quarter valued at approximately $45,000. Zacks Investment Management bought a new position in shares of OPKO Health during the fourth quarter valued at approximately $49,000. Ieq Capital LLC bought a new position in shares of OPKO Health during the fourth quarter valued at approximately $52,000. Finally, World Investment Advisors LLC bought a new position in shares of OPKO Health during the third quarter valued at approximately $61,000. Institutional investors own 64.63% of the company's stock.

OPKO Health Price Performance

OPK opened at $1.41 on Tuesday. The firm has a market cap of $946.89 million, a PE ratio of -7.42 and a beta of 1.78. The stock has a 50-day moving average price of $1.64 and a 200-day moving average price of $1.57. OPKO Health, Inc. has a 1 year low of $1.15 and a 1 year high of $2.04. The company has a debt-to-equity ratio of 0.30, a current ratio of 2.97 and a quick ratio of 2.69.

OPKO Health (NASDAQ:OPK - Get Free Report) last issued its earnings results on Thursday, February 27th. The biotechnology company reported $0.01 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.08) by $0.09. The business had revenue of $183.60 million during the quarter, compared to analysts' expectations of $155.42 million. OPKO Health had a negative net margin of 18.65% and a negative return on equity of 9.76%. Sell-side analysts predict that OPKO Health, Inc. will post -0.25 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages recently commented on OPK. Barrington Research restated an "outperform" rating and set a $2.25 target price on shares of OPKO Health in a report on Wednesday, March 12th. StockNews.com raised OPKO Health from a "sell" rating to a "hold" rating in a research note on Monday, March 3rd. JPMorgan Chase & Co. began coverage on OPKO Health in a research note on Friday. They issued a "neutral" rating on the stock. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $3.00 price target on shares of OPKO Health in a research note on Monday, April 7th. Two research analysts have rated the stock with a hold rating and three have given a buy rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $2.75.

Insiders Place Their Bets

In other news, CEO Phillip Md Et Al Frost bought 125,000 shares of the firm's stock in a transaction on Thursday, April 10th. The stock was acquired at an average cost of $1.36 per share, with a total value of $170,000.00. Following the completion of the acquisition, the chief executive officer now owns 214,001,448 shares of the company's stock, valued at approximately $291,041,969.28. This represents a 0.06 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Over the last ninety days, insiders bought 767,434 shares of company stock valued at $1,238,312. Insiders own 49.69% of the company's stock.

About OPKO Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.